Clinical pathological study of treatment of chronic
hepatitis with hyperbaric oxygenation
Liu W, Zhao W, Lu X, Zheng X, Luo C.
Department of Gastroenterology, The Affiliated Nanjing Second Hospital
of the Medical College of Nanjing Southeast University, Nanjing 210003,
China. liuwei6501@sohu.com
OBJECTIVE: To detect the feasibility and theoretic basis for treatment
with hyperbaric oxygenation (HBO) in chronic hepatitis and to compare
the changes in hepatic function, immunity, pathologic morphology,
ultrastructure and HBV in hepatic tissues before and after treatment.
METHODS: Sixty cases of chronic hepatitis were randomly selected and
divided into two groups: the experiment (n = 30) and control groups (n =
30). Patients in the experimental group were treated with HBO for 6
courses. Patients in the control group were treated for 60 days with the
usual drugs used in the clinic. The function and bloodstream graph of
liver were examined and liver biopsies were made before and after
treatments. Routine paraffin sections were stained with HE and observed
under the light microscope. Ultra thin slides from paraformaldehyde and
glutaraldehyde fixed liver tissue were stained with lead citrate and
observed with the transmission electric microscope. HBsAg and HBcAg in
liver of the experimental group were detected with ABC
immunohistochemistry method before and after treatment.
RESULTS: For the
experimental group, ALT, SB, gamma-GT, AKP, IgG, and IgM in blood and
the degeneration and necrosis of hepatocytes were remarkably decreased
(P < 0.05 ), the mean contractive wave of bloodstream in liver and
the bloodstream in right ramus of janitrix were remarkably increased (P
< 0.05), and the swelling of mitochondria, increase of lysosomes,
generation of Kupffer cells, infiltration of lymphocytes in portal area
and capillary generation were all remarkably all eviated (P < 0.05)
after treatment with HBO. There were significant differences between the
experimental and control groups after treatment with different methods
(P < 0.05). For patients in the experimental group, the fibrosis and
fat-storing cells in the liver were not reduced (P > 0.05), and the
expression of HBsAg and HBcAg in liver was not weakened (P < 0.05)
after treatment.
CONCLUSIONS: Treatment with HBO for chronic hepatitis
was effective and recommendable, but it could not reverse liver
fibrosis. However, it might be able to delay or prevent the liver from
fibrosis, so it might be more effective at the early and middle stages
of chronic hepatitis. HBO could not inhibit the HB virus. So we consider
that treatment with HBO should be simultaneous with anti HBV therapy.
Chin Med J (Engl). 2002 Aug;115(8):1153-7.
|